190 related articles for article (PubMed ID: 35718361)
1. Chronic Kidney Disease in the Transgender, Nonbinary, or Gender Diverse Person.
Collister D; Krakowsky Y; Potter E; Millar AC
Semin Nephrol; 2022 Mar; 42(2):129-141. PubMed ID: 35718361
[TBL] [Abstract][Full Text] [Related]
2. Providing Care for Transgender Persons With Kidney Disease: A Narrative Review.
Collister D; Saad N; Christie E; Ahmed S
Can J Kidney Health Dis; 2021; 8():2054358120985379. PubMed ID: 33552529
[TBL] [Abstract][Full Text] [Related]
3. Gender-Affirming Hormone Treatment and Metabolic Syndrome Among Transgender Veterans.
Hashemi L; Marijic Buljubasic A; Budoff MJ; Copeland LA; Jackson NJ; Jasuja GK; Gornbein J; Reue K
JAMA Netw Open; 2024 Jul; 7(7):e2419696. PubMed ID: 38954413
[TBL] [Abstract][Full Text] [Related]
4. Longitudinal Changes in Liver Enzyme Levels Among Transgender People Receiving Gender Affirming Hormone Therapy.
Hashemi L; Zhang Q; Getahun D; Jasuja GK; McCracken C; Pisegna J; Roblin D; Silverberg MJ; Tangpricha V; Vupputuri S; Goodman M
J Sex Med; 2021 Sep; 18(9):1662-1675. PubMed ID: 34366264
[TBL] [Abstract][Full Text] [Related]
5. Cystatin C-Based eGFR Changes during Gender-Affirming Hormone Therapy in Transgender Individuals.
van Eeghen SA; Wiepjes CM; T'Sjoen G; Nokoff NJ; den Heijer M; Bjornstad P; van Raalte DH
Clin J Am Soc Nephrol; 2023 Dec; 18(12):1545-1554. PubMed ID: 37678248
[TBL] [Abstract][Full Text] [Related]
6. Feminizing gender-affirming hormone therapy for the transgender and gender diverse population: An overview of treatment modality, monitoring, and risks.
Sudhakar D; Huang Z; Zietkowski M; Powell N; Fisher AR
Neurourol Urodyn; 2023 Jun; 42(5):903-920. PubMed ID: 36403287
[TBL] [Abstract][Full Text] [Related]
7. A Holistic Framework for the Evaluation of Kidney Function in a Gender-Diverse Landscape.
Turino Miranda K; Greene DN; Collister D; Krasowski MD; Ahmed SB; Cirrincione LR; Rosas SE; Saad N; Pierre CC
Am J Kidney Dis; 2024 Mar; ():. PubMed ID: 38458377
[TBL] [Abstract][Full Text] [Related]
8. Association of Gender-Affirming Hormone Therapy With Depression, Thoughts of Suicide, and Attempted Suicide Among Transgender and Nonbinary Youth.
Green AE; DeChants JP; Price MN; Davis CK
J Adolesc Health; 2022 Apr; 70(4):643-649. PubMed ID: 34920935
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular disease in transgender individuals.
Murphy CN; Delles C; Davies E; Connelly PJ
Atherosclerosis; 2023 Nov; 384():117282. PubMed ID: 37821271
[TBL] [Abstract][Full Text] [Related]
10. Androgenetic alopecia incidence in transgender and gender diverse populations: A retrospective comparative cohort study.
Gao JL; Sanz J; Tan N; King DS; Modest AM; Dommasch ED
J Am Acad Dermatol; 2023 Sep; 89(3):504-510. PubMed ID: 36780950
[TBL] [Abstract][Full Text] [Related]
11. The Effect of Gender-Affirming Hormone Therapy on Serum Creatinine in Transgender Individuals.
Maheshwari A; Dines V; Saul D; Nippoldt T; Kattah A; Davidge-Pitts C
Endocr Pract; 2022 Jan; 28(1):52-57. PubMed ID: 34474185
[TBL] [Abstract][Full Text] [Related]
12. Does Gender Affirming Hormone Therapy Increase the Risk of Kidney Disease?
Eckenrode HE; Carwie JC; Curtis LM
Semin Nephrol; 2022 May; 42(3):151284. PubMed ID: 36435684
[TBL] [Abstract][Full Text] [Related]
13. Transgender health and the impact of aging and menopause.
Cheung AS; Nolan BJ; Zwickl S
Climacteric; 2023 Jun; 26(3):256-262. PubMed ID: 37011669
[TBL] [Abstract][Full Text] [Related]
14. Characterising body composition and bone health in transgender individuals receiving gender-affirming hormone therapy.
Ford K; Huggins E; Sheean P
J Hum Nutr Diet; 2022 Dec; 35(6):1105-1114. PubMed ID: 35509260
[TBL] [Abstract][Full Text] [Related]
15. Lipid profiles and hypertriglyceridemia among transgender and gender diverse adults on gender-affirming hormone therapy.
Leemaqz SY; Kyinn M; Banks K; Sarkodie E; Goldstein D; Irwig MS
J Clin Lipidol; 2023; 17(1):103-111. PubMed ID: 36473821
[TBL] [Abstract][Full Text] [Related]
16. Assessing and Addressing the Risk of Venous Thromboembolism Across the Spectrum of Gender Affirming Care: A Review.
Arrington-Sanders R; Connell NT; Coon D; Dowshen N; Goldman AL; Goldstein Z; Grimstad F; Javier NM; Kim E; Murphy M; Poteat T; Radix A; Schwartz A; St Amand C; Streed CG; Tangpricha V; Toribio M; Goldstein RH
Endocr Pract; 2023 Apr; 29(4):272-278. PubMed ID: 36539066
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular outcomes in transgender individuals in Sweden after initiation of gender-affirming hormone therapy.
Karalexi MA; Frisell T; Cnattingius S; Holmberg D; Holmberg M; Kollia N; Skalkidou A; Papadopoulos FC
Eur J Prev Cardiol; 2022 Nov; 29(15):2017-2026. PubMed ID: 35778824
[TBL] [Abstract][Full Text] [Related]
18. The Effect of Gender-Affirming Hormone Therapy on Measures of Kidney Function: A Systematic Review and Meta-Analysis.
Krupka E; Curtis S; Ferguson T; Whitlock R; Askin N; Millar AC; Dahl M; Fung R; Ahmed SB; Tangri N; Walsh M; Collister D
Clin J Am Soc Nephrol; 2022 Sep; 17(9):1305-1315. PubMed ID: 35973728
[TBL] [Abstract][Full Text] [Related]
19. Reference Intervals for Clinical Chemistry Analytes for Transgender Men and Women on Stable Hormone Therapy.
Humble RM; Greene DN; Schmidt RL; Winston McPherson G; Rongitsch J; Imborek KL; Nisly N; Dole NJ; Dane SK; Frerichs J; Krasowski MD
J Appl Lab Med; 2022 Sep; 7(5):1131-1144. PubMed ID: 35584132
[TBL] [Abstract][Full Text] [Related]
20. The effect of gender-affirming hormone treatment on serum creatinine in transgender and gender-diverse youth: implications for estimating GFR.
Millington K; Barrera E; Daga A; Mann N; Olson-Kennedy J; Garofalo R; Rosenthal SM; Chan YM
Pediatr Nephrol; 2022 Sep; 37(9):2141-2150. PubMed ID: 35083530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
